NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio's ANVS-25002 open-label Parkinson's disease clinical trial. NeuroRPM's platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson's motor symptoms.

The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson's disease across multiple clinical sites. Eligible participants may choose to take part in the NeuroRPM digital monitoring program to complement scheduled study assessments with continuous real-world symptom monitoring.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.